Treatment Of Newly Diagnosed, High-Grade, Malignant Glioma With Polifeprosan 20 Containing Carmustine Implant (Gliadel Wafer) Using MR Spectroscopy Data As A Primary Indicator Of Therapeutic Response.

Trial Profile

Treatment Of Newly Diagnosed, High-Grade, Malignant Glioma With Polifeprosan 20 Containing Carmustine Implant (Gliadel Wafer) Using MR Spectroscopy Data As A Primary Indicator Of Therapeutic Response.

Discontinued
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 May 2010

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms Gliadel-MRS
  • Most Recent Events

    • 26 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top